New Advance in Whole Genome Sequencing Analysis for Early Cancer Detection

Dear Colleagues,

A new Special Issue entitled “New Advances in Whole Genome Sequencing Analysis for Early Cancer Detection" is now open for submissions. We cordially invite you to participate in this endeavor.

This Special Issue aims to spotlight the latest cutting-edge developments in the realm of utilizing whole genome sequencing for the early detection of cancer. Our primary objective is to showcase breakthrough methodologies, advanced technologies, and innovative approaches that have the potential to revolutionize the landscape of early cancer detection. Recognizing the paramount importance of timely cancer identification in enhancing patient outcomes, researchers and scientists are diligently exploring novel avenues to harness the full potential of whole genome sequencing.

We welcome contributions covering a wide spectrum of topics, including, but not limited to, advancements in sequencing technology, the identification of biomarkers, practical clinical applications, insightful case studies and clinical trials, and the vital ethical and regulatory considerations that accompany this field. Authors with expertise in this domain are encouraged to submit original research articles or review papers that delve into this critical and rapidly evolving area.

The aim of this Special Issue is to cultivate collaboration among researchers, clinicians, and experts, all with the shared objective of propelling our understanding of how whole genome sequencing can be effectively harnessed to elevate strategies for early cancer detection. By shedding light on both breakthroughs and challenges, this Special Issue seeks to make meaningful contributions to the ongoing endeavors aimed at refining cancer outcomes via early intervention and the principles of personalized medicine.

Dr. Liang Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• bioinformatics analysis
• early cancer diagnosis
• advanced sequencing technologies
• cancer genome sequencing
• cancer genomics
• biomarkers